What is frontotemporal dementia? All about the condition Bruce Willis suffers from (early signs to watch out for)

The ‘Die Hard’ Hollywood legend Bruce Willis, reportedly, has become non-verbal and immobile now, as his battle with frontotemporal dementia worsens. Known for his decades-spanning career in action, drama, and comedy, Willis officially stepped away from acting in 2022 following a diagnosis of aphasia and was later diagnosed with frontotemporal dementia, a progressive neurological condition that affects personality, language, and motor skills.

Although there have been rumors that Willis is bedridden or losing his speech, Emma Heming Willis, his wife, set the record straight when she posted a clear message to both fans and the media on her Instagram Stories, saying: "To Whom It May Concern: If you ever come across a story that begins with "sources close to the family say...," do yourself a favor and stop reading."

But what is frontotemporal dementia (FTD)? How does it affect personality, language, and motor skills?

What is frontotemporal dementia (FTD)

Frontotemporal dementia, also known as frontotemporal degeneration (FTD), encompasses a group of disorders caused by progressive nerve cell loss in the brain’s frontal and temporal lobes. These lobes govern personality, emotional regulation, language, and movement. Over time, the affected brain regions shrink and connectivity breaks down, leading to significant cognitive and behavioral symptoms.

FTD is rare but devastating; unlike Alzheimer’s, it often strikes between the ages of 45 and 65, though cases can appear earlier or later. FTD accounts for approximately 10–20% of all dementia diagnoses and is the most common form in individuals under 60.

Subtypes of FTD

Behavioral‑variant FTD (bvFTD): The most frequent type, formerly known as Pick’s disease, is characterized by changes in personality and behavior such as impulsivity, apathy, inappropriate social conduct, poor judgment, and compulsions.

Primary progressive aphasia (PPA): A language‑based variant affecting speech production or comprehension. Within this group are:

Non‑fluent variant (nfvPPA): stumbling or labored speech.

Semantic variant (svPPA): loss of word meaning and object recognition

Movement‑related FTD: Though less common, it is associated with disorders such as corticobasal syndrome, progressive supranuclear palsy, or ALS‑related FTD, leading to tremors, stiffness, or mobility issues.

Risk factors

Frontotemporal dementia (FTD) risk factors include a family history of FTD (especially a parent or sibling with FTD), genetic mutations, and possibly head trauma. While some cases are familial and linked to specific genes, most are considered sporadic, with no clear family history. Other factors like age (most common between 40 and 65) and certain lifestyle factors (like head injuries) may also play a role.

FTD often results from abnormal protein buildup in brain cells, including tau or TDP-43, leading to cell death and lobar atrophy. About 30–50% of cases involve a genetic component; mutations in genes like MAPT, PGRN, or C9ORF72 are common culprits.

Early signs to watch for

Recognizing FTD early can be challenging, as symptoms are often mistaken for psychiatric issues or stress. Typical early signs include:

Personality or behavior changes: Reduced empathy, inappropriate social conduct, impulsivity, apathy, neglect of hygiene, compulsions.

Language difficulties: Difficulty speaking or understanding language, word-finding problems, simplified or hesitant speech.

Executive dysfunction: Problems with planning, organizing, and multitasking; distractions increase.

Emerging motor symptoms (in some): Tremors, stiffness, poor coordination, swallowing issues, or difficulty walking emerge later in certain variants.

Diagnosis and prognosis

Diagnosis involves neurological exam, cognitive testing, gathering detailed medical history (often from family), and imaging such as MRI or PET to detect frontal and/or temporal lobe shrinkage or metabolic changes. FTD typically progresses steadily, with survival ranging from 2 to 20 years, averaging around 6–10 years post-diagnosis.

There is no cure or disease-modifying treatment for FTD. Management focuses on addressing symptoms, providing support, and improving quality of life. Treatment strategies include medications for behavioral and mood changes, speech and physical therapy, and strategies for managing daily living tasks and communication. Furthermore, selective serotonin reuptake inhibitors (SSRIs) are administered to reduce disinhibition, while speech, occupational, and behavioral therapies assist daily function.